Table 2 |
|||
|
Co-immunization of DR4 transgenic mice with type II collagen (CII) and analog peptides |
|||
| Immunizing antigen |
Core of co-immunogen |
Incidence of arthritis |
CII antibodies |
|
|
|||
| CII alone |
FKGEQGPKG |
11/18 (61%) |
61 ± 11 |
| CII + A13 (1:480) |
N--A----- |
0/10a |
7 ± 2b |
| CII + A12 (1:480) |
N--D----- |
0/16b |
16 ± 9b |
| CII + D266 (1:480) |
---D----- |
7/10 (70%) |
48 ± 13 |
|
|
|||
|
Groups of DR4 transgenic mice were co-immunized with CII alone or CII plus an analog peptide at the molar ratios indicated, and were observed for arthritis. These doses were based on dose-response curves obtained using DR1 mice [12]. Results shown represent the incidence of arthritis observed at 8 weeks after immunization. Mice were bled at 6 weeks after immunization, and sera were analyzed individually by enzyme-linked immunosorbent assay to determine antibody levels against bovine CII. Results are means ± SD for each group of animals and are expressed in units of activity. ap ≤ 0.01; bp ≤ 0.001. |
|||
|
Sakurai et al. Arthritis Research & Therapy 2006 8:R150 doi:10.1186/ar2043 |
|||
